Dr. Howard J. Federoff, M.D., Ph.D.,

CEO and President
Brooklyn ImmunoTherapeutics
(NASDAQ: BTX)

Dr. Howard J. Federoff, M.D., Ph.D., brings a wealth of experience to BTX, including his previous tenure as CEO of Aspen Neuroscience, Inc. and as co-founder of both MedGenesis Therapeutix and Brain Neurotherapy Bio. Before that, he served in the University of California Irvine Health System as CEO, Vice Chancellor for Health Affairs, and Dean of the School of Medicine after also being Executive VP for Health Sciences and Executive Dean of the School of Medicine at Georgetown University. Dr. Federoff chaired the NIH Recombinant DNA Advisory Committee, the National Heart, Lung, and Blood Institute Gene Therapy Group, and the Board of the Association of the Academic Health Centers.

Dr. Federoff is formerly a distinguished Professor of Neurology at UC Irvine School of Medicine, an elected Fellow of the American Association for the Advancement of Science and the National Academy of Inventors, and on the editorial board of five journals. He holds a MD, MS, and PhD in biochemistry from the Albert Einstein College of Medicine of Yeshiva and has published more than 275 peer-reviewed and invited articles.